Corrigendum to “Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database” Eur J Cancer. 2023 Jan;178:162–170

The authors regret that Fig. 2B was accidently excluded from the final manuscript. This has now been corrected. The authors would like to apologise for any inconvenience caused.

Source: European Journal of Cancer - September 28, 2023 Category: Cancer & Oncology Authors: Ofer Margalit, William S. Harmsen, Einat Shacham-Shmueli, Molly M. Voss, Ben Boursi, Anna D. Wagner, Romain Cohen, Curtis L. Olswold, Leonard B. Saltz, Daniel A. Goldstein, Herbert Hurwitz, Niall C. Tebbutt, Fairooz F. Kabbinavar, Richard A. Adams, Benois Tags: Corrigendum Source Type: research